| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5822697 | Antiviral Research | 2012 | 10 Pages |
Abstract
⺠Global economic burden of dengue was US $1.7 billion in 2006. ⺠Maximum potential market for dengue drugs is US $338 million per annum. ⺠Potential sales of a dengue drug exceed drug R + D costs. ⺠Dengue vaccines will not substantially impact potential sales of a dengue drug. ⺠Drug pricing based on shared division of economic costs is an alternative to tiered pricing.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Geoffrey Dow, Eric Mora,